Current Clinical Psychopharmacology in Borderline Personality Disorder

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Psychology

Background:

• Borderline Personality Disorder (BPD) presents significant personal distress, relationship challenges, and functional impairment.
• High healthcare costs are associated with managing BPD, particularly for patients unresponsive to psychological treatments.
• Medication is frequently prescribed for BPD, especially when psychological interventions are insufficient.

Purpose of the Study:

• To comprehensively review the efficacy of common pharmacological interventions for Borderline Personality Disorder.
• To provide an overview of the current landscape of drug treatments used in BPD management.

Main Methods:

• Systematic search of PubMed for randomized controlled trials and open studies on psychotropic drugs for BPD.
• Inclusion of adult patients diagnosed with BPD.
• Focus on drug efficacy and tolerability for specific BPD symptom clusters.

Main Results:

• Second-generation antipsychotics (SGAs) and serotonergic antidepressants are effective for core BPD symptoms like mood instability, anxiety, and impulsivity.
• Atypical antipsychotics demonstrate efficacy in managing psychotic and dissociative symptoms associated with BPD.
• Antiepileptic drugs show utility in addressing mood lability, impulsiveness, and anger in some BPD cases.

Conclusions:

• Currently, no single medication is FDA-approved for BPD treatment.
• Clinicians must carefully weigh the benefits against the risks of pharmacotherapy in BPD.
• Further research is essential to develop personalized treatment strategies, acknowledging BPD's heterogeneity and comorbidities.